Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
vazkepa save search
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
| Email alert
Add to watchlist
disease cardiovascular show
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in EuropeCompany’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 3.03%
H: 8.82%
C: 3.92%
vazkepa europe update
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 3.03%
H: 8.82%
C: 3.92%
vazkepa europe update
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 1.2%
H: 0.99%
C: -3.0%
vascepa expo research benefits
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
Published: 2023-10-26 (Crawled : 12:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: -3.19%
H: 4.99%
C: 0.3%
vascepa association sessions research heart trial
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
Published: 2023-08-09 (Crawled : 20:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 1.72%
H: 0.0%
C: -5.93%
netherlands vazkepa
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
Published: 2023-08-08 (Crawled : 11:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
vazkepa israel commercialization agreement
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
Published: 2023-08-07 (Crawled : 11:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: -4.55%
H: 0.0%
C: 0.0%
vazkepa risk cardiovascular
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Published: 2023-07-31 (Crawled : 12:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 0.0%
H: 7.56%
C: 0.84%
vazkepa partnership pharmaceuticals asia agreement
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
Published: 2023-07-26 (Crawled : 12:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: -3.83%
H: 2.65%
C: 0.88%
vascepa research cardiology benefits
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
Published: 2023-07-25 (Crawled : 20:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: -3.83%
H: 2.65%
C: 0.88%
vazkepa drug positive
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
Published: 2023-07-18 (Crawled : 20:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: -20.28%
H: 6.58%
C: -5.26%
vascepa
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
Published: 2023-05-12 (Crawled : 15:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 1.69%
H: 3.33%
C: 2.5%
vascepa cardiovascular potential
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
Published: 2023-04-04 (Crawled : 14:00) - biospace.com/
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: -0.67%
H: 1.35%
C: -3.38%
vazkepa health approved
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 0.0%
H: 8.88%
C: 7.24%
vascepa ready potential
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
Published: 2023-03-05 (Crawled : 20:20) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
| Email alert
Add to watchlist
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
Published: 2023-02-28 (Crawled : 13:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 0.0%
H: 17.93%
C: 10.33%
vazkepa australia distribution license agreement
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
Published: 2023-02-27 (Crawled : 17:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 1.69%
H: 3.61%
C: 2.22%
vascepa corporation
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCCPresentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress
Published: 2023-02-27 (Crawled : 16:00) - biospace.com/
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 1.69%
H: 3.61%
C: 2.22%
vascepa in-vitro corporation in vitro
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
Published: 2023-01-27 (Crawled : 14:00) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 1.66%
H: 5.98%
C: 0.54%
vazkepa approved
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.